ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma
Head & Neck · 2024
DOI: 10.1002/hed.27635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, 2024. Verfasst von Pedro Nicolau-Neto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Programa de Carcinogênese Molecular, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Carcinoma, Squamous Cell, Head and Neck Neoplasms. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Swiss Bridge Foundation, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background
Laryngeal squamous cell carcinoma (LSCC) is the second most frequent head and neck tumor. Prognosis of patients with LSCC has not improved in recent decades, showing a need for the identification of prognostic biomarkers and new therapeutic targets. Recently, we showed that ALCAM overexpression was associated with glottic LSCC prognosis. Objectives and methods Aiming to validate the prognostic value of ALCAM, we evaluate the ALCAM protein levels by immunohistochemistry in 263 glottic LSCC surgically treated with neck dissection.
Results
ALCAM was expressed in 48.7% and overexpressed in 36.5% of glottic LSCC samples. ALCAM overexpression was associated with lymph node metastasis ( p = 0.030), lymphovascular involvement ( p = 0.0002), high‐grade tumors ( p = 0.025), and tumor relapse ( p = 0.043). Multivariate survival analyses showed an overfitting between ALCAM overexpression and lymph node metastasis as a prognostic variable.
Conclusions
High ALCAM expression was associated with an aggressive glottic LSCC profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Programa de Carcinogênese Molecular, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil.
- Seção de Cirurgia de Cabeça e Pescoço, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil.
- Biologia Molecular, Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
- Divisão de Patologia, Instituto Nacional de Câncer-INCA, Rio de Janeiro, Brazil.
- Departamento de Bioquímica, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil.
ORCID-Profile: Pedro Nicolau-Neto
Förderung
- Swiss Bridge Foundation
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Nicolau-Neto, P., Peryassú, B. C., de Carvalho, F. N., Souza-Santos, P. T., Valverde, P., Nascimento, C. M., Costa, I., Dias, F. L., & Pinto, L. F. R. (2024). ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma. Head & Neck. https://doi.org/10.1002/hed.27635
Vancouver
Nicolau-Neto P, Peryassú BC, de Carvalho FN, Souza-Santos PT, Valverde P, Nascimento CM, et al. ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma. Head & Neck. 2024. doi:10.1002/hed.27635
BibTeX
@article{NicolauNeto2024,
author = {Nicolau-Neto, Pedro and Peryassú, Bernardo Cacciari and de Carvalho, Flávia Nascimento and Souza-Santos, Paulo Thiago and Valverde, Priscila and Nascimento, Cristina Moreira and Costa, Izabella and Dias, Fernando L and Pinto, Luis Felipe Ribeiro},
title = {ALCAM is a biomarker of tumor aggressiveness and worse prognosis in glottic laryngeal squamous cell carcinoma},
journal = {Head & Neck},
year = {2024},
doi = {10.1002/hed.27635}
}
EUVIMED